Novel triple-drug HCV combo achieves high SVR Direct-acting investigational "three-D" combination therapy achieves more than 99% sustained virologic response in patients hepatitis C genotype 1b.
NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with ...
AMSTERDAM, April 20, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 99 percent (n=145/146) of chronic hepatitis C virus (HCV) infected patients with ...
AbbVie may have an edge over Gilead in the race to bring a faster-acting, all-oral hepatitis C cure to market, but it’s a slight one. Yesterday the drugmaker presented detailed Phase-III data for its ...
In a modified intent-to-treat (mITT) analysis, SVR 12 was achieved in 100 percent (n=102/102) of severe CKD patients. The mITT analysis excludes patients who did not achieve SVR for reasons other than ...
In more than 700 chronic HCV patients without cirrhosis who were infected with one of genotypes 1-6 (GT1-6) and were new to treatment, 97.5 percent (n=693/711) achieved sustained virologic response at ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Of those who completed treatment, 92% had undetectable ...
Healthcare worker HIV PEP guidelines updated Rates of sustained virologic response ranged from 70% to 90% among patients with HCV and HIV coinfection in the PHOTON-1 study. The first interferon-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results